Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

PARP inhibition in BRCA2-mutated prostate cancer.

Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. No abstract available.

PMID:
31792512
2.

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK rearranged lung cancer.

Dietz S, Christopoulos P, Gu L, Volckmar AL, Endris V, Yuan Z, Ogrodnik SJ, Zemojtel T, Heussel CP, Schneider MA, Meister M, Muley T, Reck M, Schlesner M, Thomas M, Stenzinger A, Sültmann H.

Cold Spring Harb Mol Case Stud. 2019 Nov 21. pii: mcs.a004630. doi: 10.1101/mcs.a004630. [Epub ahead of print]

3.

Circulating MicroRNAs as Potential Biomarkers for Lung Cancer.

Müller S, Janke F, Dietz S, Sültmann H.

Recent Results Cancer Res. 2020;215:299-318. doi: 10.1007/978-3-030-26439-0_16. Review.

PMID:
31605236
4.

The BRCA2 mutation status shapes the immune phenotype of prostate cancer.

Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S.

Cancer Immunol Immunother. 2019 Oct;68(10):1621-1633. doi: 10.1007/s00262-019-02393-x. Epub 2019 Sep 23.

5.

Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.

Willbold R, Wirth K, Martini T, Sültmann H, Bolenz C, Wittig R.

Cell Death Dis. 2019 Aug 9;10(8):601. doi: 10.1038/s41419-019-1830-8.

6.

Defining molecular risk in ALK+ NSCLC.

Christopoulos P, Budczies J, Kirchner M, Dietz S, Sültmann H, Thomas M, Stenzinger A.

Oncotarget. 2019 May 3;10(33):3093-3103. doi: 10.18632/oncotarget.26886. eCollection 2019 May 3.

7.

Multiple layers of intratumor heterogeneity: clues to clonal evolution of non-small cell lung cancer.

Dietz S, Kazdal D, Sültmann H.

Oncotarget. 2019 Feb 22;10(16):1549-1551. doi: 10.18632/oncotarget.26708. eCollection 2019 Feb 22. No abstract available.

8.

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.

Christopoulos P, Dietz S, Kirchner M, Volckmar AL, Endris V, Neumann O, Ogrodnik S, Heussel CP, Herth FJ, Eichhorn M, Meister M, Budczies J, Allgäuer M, Leichsenring J, Zemojtel T, Bischoff H, Schirmacher P, Thomas M, Sültmann H, Stenzinger A.

Cancers (Basel). 2019 Jan 21;11(1). pii: E124. doi: 10.3390/cancers11010124.

9.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

PMID:
30537516
10.

Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancer.

Weber R, Meister M, Muley T, Thomas M, Sültmann H, Warth A, Winter H, Herth FJF, Schneider MA.

Int J Oncol. 2019 Feb;54(2):515-526. doi: 10.3892/ijo.2018.4654. Epub 2018 Dec 5.

11.

Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.

Kesch C, Radtke JP, Wintsche A, Wiesenfarth M, Luttje M, Gasch C, Dieffenbacher S, Pecqueux C, Teber D, Hatiboglu G, Nyarangi-Dix J, Simpfendörfer T, Schönberg G, Dimitrakopoulou-Strauss A, Freitag M, Duensing A, Grüllich C, Jäger D, Götz M, Grabe N, Schweiger MR, Pahernik S, Perner S, Herpel E, Roth W, Wieczorek K, Maier-Hein K, Debus J, Haberkorn U, Giesel F, Galle J, Hadaschik B, Schlemmer HP, Hohenfellner M, Bonekamp D, Sültmann H, Duensing S.

Sci Rep. 2018 Nov 12;8(1):16708. doi: 10.1038/s41598-018-35058-3.

12.

Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma.

Zabeck H, Dienemann H, Hoffmann H, Pfannschmidt J, Warth A, Schnabel PA, Muley T, Meister M, Sültmann H, Fröhlich H, Kuner R, Lasitschka F.

PLoS One. 2018 Oct 23;13(10):e0206132. doi: 10.1371/journal.pone.0206132. eCollection 2018.

13.

Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.

Dietz S, Lifshitz A, Kazdal D, Harms A, Endris V, Winter H, Stenzinger A, Warth A, Sill M, Tanay A, Sültmann H.

Int J Cancer. 2019 Mar 1;144(5):1061-1072. doi: 10.1002/ijc.31939. Epub 2018 Dec 3.

PMID:
30350867
14.

Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.

Volckmar AL, Endris V, Gaida MM, Leichsenring J, Stögbauer F, Allgäuer M, von Winterfeld M, Penzel R, Kirchner M, Brandt R, Neumann O, Sültmann H, Schirmacher P, Rudi J, Schmitz D, Stenzinger A.

Genes Chromosomes Cancer. 2019 Jan;58(1):3-11. doi: 10.1002/gcc.22682. Epub 2018 Oct 17.

PMID:
30230086
15.

Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma.

Kazdal D, Longuespée R, Dietz S, Casadonte R, Schwamborn K, Volckmar AL, Kriegsmann J, Kriegsmann K, Fresnais M, Stenzinger A, Sültmann H, Warth A, Kriegsmann M.

Proteomics Clin Appl. 2019 Jan;13(1):e1800034. doi: 10.1002/prca.201800034. Epub 2018 Oct 15.

PMID:
30216696
16.

Genome-Based Classification and Therapy of Prostate Cancer.

Angeles AK, Bauer S, Ratz L, Klauck SM, Sültmann H.

Diagnostics (Basel). 2018 Sep 2;8(3). pii: E62. doi: 10.3390/diagnostics8030062. Review.

17.

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.

Grasse S, Lienhard M, Frese S, Kerick M, Steinbach A, Grimm C, Hussong M, Rolff J, Becker M, Dreher F, Schirmer U, Boerno S, Ramisch A, Leschber G, Timmermann B, Grohé C, Lüders H, Vingron M, Fichtner I, Klein S, Odenthal M, Büttner R, Lehrach H, Sültmann H, Herwig R, Schweiger MR.

Genome Med. 2018 Jul 20;10(1):55. doi: 10.1186/s13073-018-0562-1.

18.

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.

Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S.

Urol Oncol. 2018 Aug;36(8):365.e15-365.e26. doi: 10.1016/j.urolonc.2018.05.020. Epub 2018 Jun 7.

PMID:
29887238
19.

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL.

Dieffenbacher S, Zschäbitz S, Hofer L, Hatiboglu G, Hou W, Hohenfellner M, Duensing S, Sültmann H, Pahernik S, Grüllich C.

Future Sci OA. 2018 Mar 14;4(5):FSO299. doi: 10.4155/fsoa-2017-0150. eCollection 2018 Jun. Review.

20.

Genomic features of renal cell carcinoma with venous tumor thrombus.

Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S.

Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z.

21.

Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes.

Zhang Z, Filzmayer C, Ni Y, Sültmann H, Mutz P, Hiet MS, Vondran FWR, Bartenschlager R, Urban S.

J Hepatol. 2018 Jul;69(1):25-35. doi: 10.1016/j.jhep.2018.02.021. Epub 2018 Mar 8.

PMID:
29524530
22.

A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.

Volckmar AL, Sültmann H, Riediger A, Fioretos T, Schirmacher P, Endris V, Stenzinger A, Dietz S.

Genes Chromosomes Cancer. 2018 Mar;57(3):123-139. doi: 10.1002/gcc.22517. Epub 2017 Dec 20. Review.

PMID:
29205637
23.

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S.

Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.

PMID:
29198908
24.

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.

Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S.

Oncotarget. 2017 May 23;8(43):74049-74057. doi: 10.18632/oncotarget.18200. eCollection 2017 Sep 26.

25.

Identification of E6/E7-Dependent MicroRNAs in HPV-Positive Cancer Cells.

Honegger A, Schilling D, Sültmann H, Hoppe-Seyler K, Hoppe-Seyler F.

Methods Mol Biol. 2018;1699:119-134. doi: 10.1007/978-1-4939-7435-1_10.

PMID:
29086374
26.

Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.

Dietz S, Harms A, Endris V, Eichhorn F, Kriegsmann M, Longuespée R, Stenzinger A, Sültmann H, Warth A, Kazdal D.

Int J Cancer. 2017 Nov 1;141(9):1841-1848. doi: 10.1002/ijc.30881. Epub 2017 Jul 24.

27.

Mutations in BRCA2 and taxane resistance in prostate cancer.

Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x.

28.

TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.

Ratz L, Laible M, Kacprzyk LA, Wittig-Blaich SM, Tolstov Y, Duensing S, Altevogt P, Klauck SM, Sültmann H.

Oncotarget. 2017 Apr 11;8(15):25115-25130. doi: 10.18632/oncotarget.15931.

29.

Experimental design and data analysis of Ago-RIP-Seq experiments for the identification of microRNA targets.

Tichy D, Pickl JMA, Benner A, Sültmann H.

Brief Bioinform. 2018 Sep 28;19(5):918-929. doi: 10.1093/bib/bbx032.

PMID:
28379479
30.

QSEA-modelling of genome-wide DNA methylation from sequencing enrichment experiments.

Lienhard M, Grasse S, Rolff J, Frese S, Schirmer U, Becker M, Börno S, Timmermann B, Chavez L, Sültmann H, Leschber G, Fichtner I, Schweiger MR, Herwig R.

Nucleic Acids Res. 2017 Apr 7;45(6):e44. doi: 10.1093/nar/gkw1193.

31.

PARP inhibition in BRCA2-mutated prostate cancer.

Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. No abstract available.

PMID:
27687312
32.

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.

Riediger AL, Dietz S, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, Muley T, Thomas M, Sültmann H.

Sci Rep. 2016 Sep 19;6:33505. doi: 10.1038/srep33505.

33.

Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.

Dietz S, Schirmer U, Mercé C, von Bubnoff N, Dahl E, Meister M, Muley T, Thomas M, Sültmann H.

PLoS One. 2016 Aug 16;11(8):e0161012. doi: 10.1371/journal.pone.0161012. eCollection 2016.

34.

Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.

Pickl JM, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Schüler J, Reidenbach D, Hotz-Wagenblatt A, Kristiansen G, Roth W, Hadaschik B, Hohenfellner M, Duensing S, Heckmann D, Sültmann H.

Oncotarget. 2016 Sep 13;7(37):59589-59603. doi: 10.18632/oncotarget.10729.

35.

A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.

Castelo-Branco P, Leão R, Lipman T, Campbell B, Lee D, Price A, Zhang C, Heidari A, Stephens D, Boerno S, Coelho H, Gomes A, Domingos C, Apolonio JD, Schäfer G, Bristow RG, Schweiger MR, Hamilton R, Zlotta A, Figueiredo A, Klocker H, Sültmann H, Tabori U.

Oncotarget. 2016 Sep 6;7(36):57726-57736. doi: 10.18632/oncotarget.10639.

36.

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.

Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S.

Nat Commun. 2016 Jun 13;7:ncomms11845. doi: 10.1038/ncomms11845.

37.

Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer.

Praveen P, Hülsmann H, Sültmann H, Kuner R, Fröhlich H.

Sci Rep. 2016 Jun 9;6:27514. doi: 10.1038/srep27514.

38.

Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment.

Ridder K, Sevko A, Heide J, Dams M, Rupp AK, Macas J, Starmann J, Tjwa M, Plate KH, Sültmann H, Altevogt P, Umansky V, Momma S.

Oncoimmunology. 2015 Mar 19;4(6):e1008371. eCollection 2015 Jun.

39.

Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells.

Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sültmann H, Scheffner M, Hoppe-Seyler K, Hoppe-Seyler F.

PLoS Pathog. 2015 Mar 11;11(3):e1004712. doi: 10.1371/journal.ppat.1004712. eCollection 2015 Mar.

40.

[Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications].

Höfflin R, Roth W, Sültmann H, Grüllich C, Hatiboglu G, Nyarangi-Dix J, Schönberg G, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S.

Urologe A. 2015 Jun;54(6):800-3. doi: 10.1007/s00120-015-3800-9. Review. German.

PMID:
25758237
41.

BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence.

Gu L, Frommel SC, Oakes CC, Simon R, Grupp K, Gerig CY, Bär D, Robinson MD, Baer C, Weiss M, Gu Z, Schapira M, Kuner R, Sültmann H, Provenzano M; ICGC Project on Early Onset Prostate Cancer, Yaspo ML, Brors B, Korbel J, Schlomm T, Sauter G, Eils R, Plass C, Santoro R.

Nat Genet. 2015 Jan;47(1):22-30. doi: 10.1038/ng.3165. Epub 2014 Dec 8.

PMID:
25485837
42.

Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains.

Pandey V, Sultan M, Kashofer K, Ralser M, Amstislavskiy V, Starmann J, Osprian I, Grimm C, Hache H, Yaspo ML, Sültmann H, Trauner M, Denk H, Zatloukal K, Lehrach H, Wierling C.

PLoS One. 2014 Oct 27;9(10):e111006. doi: 10.1371/journal.pone.0111006. eCollection 2014.

43.

Novel RNA markers in prostate cancer: functional considerations and clinical translation.

Pickl JM, Heckmann D, Ratz L, Klauck SM, Sültmann H.

Biomed Res Int. 2014;2014:765207. doi: 10.1155/2014/765207. Epub 2014 Aug 28. Review.

44.

Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.

Hülsmann HJ, Rolff J, Bender C, Jarahian M, Korf U, Herwig R, Fröhlich H, Thomas M, Merk J, Fichtner I, Sültmann H, Kuner R.

Lung Cancer. 2014 Nov;86(2):151-7. doi: 10.1016/j.lungcan.2014.09.001. Epub 2014 Sep 10.

PMID:
25240516
45.

Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).

Georgi B, Korzeniewski N, Hadaschik B, Grüllich C, Roth W, Sültmann H, Pahernik S, Hohenfellner M, Duensing S.

Int J Oncol. 2014 Oct;45(4):1337-44. doi: 10.3892/ijo.2014.2567. Epub 2014 Jul 28. Review.

PMID:
25070358
46.

Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation.

Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Del Turco D, Starmann J, Macas J, Karpova D, Devraj K, Depboylu C, Landfried B, Arnold B, Plate KH, Höglinger G, Sültmann H, Altevogt P, Momma S.

PLoS Biol. 2014 Jun 3;12(6):e1001874. doi: 10.1371/journal.pbio.1001874. eCollection 2014 Jun. Erratum in: PLoS Biol. 2018 Mar 12;16(3):e1002623.

47.

The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.

Hussong M, Börno ST, Kerick M, Wunderlich A, Franz A, Sültmann H, Timmermann B, Lehrach H, Hirsch-Kauffmann M, Schweiger MR.

Cell Death Dis. 2014 Apr 24;5:e1195. doi: 10.1038/cddis.2014.157.

48.

Long noncoding RNA: "LNCs" to cancer.

Sültmann H, Diederichs S.

Eur Urol. 2014 Jun;65(6):1152-3. doi: 10.1016/j.eururo.2014.01.032. Epub 2014 Jan 31. No abstract available.

PMID:
24508069
49.

Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.

Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P.

Oncotarget. 2014 Jan 30;5(2):462-72.

50.

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S.

Gastroenterology. 2014 Apr;146(4):1070-83. doi: 10.1053/j.gastro.2013.12.024. Epub 2013 Dec 19.

PMID:
24361467

Supplemental Content

Loading ...
Support Center